Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Roche’s Actemra Improves COVID-19 Survival, Study Claims

  • Post author:Sam
  • Post published:November 19, 2020
  • Post category:Drug Industry Daily

The Roche Group’s rheumatoid arthritis drug Actemra (tocilizumab) was found to reduce mortality and improve outcomes for high-risk COVID-19 patients, according to researchers from the UK’s Imperial College London. Source:…

Continue ReadingRoche’s Actemra Improves COVID-19 Survival, Study Claims

AstraZeneca Vaccine Results Likely By Christmas, With Early Efficacy Findings in Weeks

  • Post author:Sam
  • Post published:November 19, 2020
  • Post category:Drug Industry Daily

Researchers at the University of Oxford expect to report results from their phase 3 trials of AstraZeneca’s (AZ) COVID-19 vaccine candidate, AZD1222, before Christmas, the study’s leader said. Source: Drug…

Continue ReadingAstraZeneca Vaccine Results Likely By Christmas, With Early Efficacy Findings in Weeks

Sanofi Gets Priority Review for Investigational Enzyme Therapy

  • Post author:Sam
  • Post published:November 19, 2020
  • Post category:Drug Industry Daily

The FDA has granted a priority review to Sanofi’s biologics license application (BLA) for an experimental enzyme replacement therapy for patients suffering from Pompe disease, a rare illness that causes…

Continue ReadingSanofi Gets Priority Review for Investigational Enzyme Therapy

FDA Issues Advice on Cross Labeling for Oncology Drugs

  • Post author:Sam
  • Post published:November 19, 2020
  • Post category:Drug Industry Daily

The FDA released a draft guidance yesterday with proposed recommendations for making changes to the labeling of a previously approved oncology drug that describes how to use the drug in…

Continue ReadingFDA Issues Advice on Cross Labeling for Oncology Drugs

How Moderna is Taking on the Pharma Giants With its COVID-19 Vaccine

  • Post author:Sam
  • Post published:November 19, 2020
  • Post category:Drug Industry Daily

As some of the world’s largest drugmakers gear up to manufacture and distribute COVID-19 vaccines, a relatively tiny competitor, Massachusetts-based Moderna, faces some unique challenges. Source: Drug Industry Daily

Continue ReadingHow Moderna is Taking on the Pharma Giants With its COVID-19 Vaccine

Meet Sooner With Us, Biosimilars Industry Asks FDA

  • Post author:Sam
  • Post published:November 19, 2020
  • Post category:Drug Industry Daily

Better communications between the FDA and sponsors, and more clarity from the agency on the issue of interchangeability, were among the suggestions from industry yesterday at a public meeting on…

Continue ReadingMeet Sooner With Us, Biosimilars Industry Asks FDA

IMDRF Advances Device Conformity Assessment Documents

  • Post author:Sam
  • Post published:November 6, 2020
  • Post category:The GMP Letter

The International Medical Device Regulators Forum (IMDRF) made some progress toward global harmonization of device standards at its most recent meeting — held for the first time as a virtual…

Continue ReadingIMDRF Advances Device Conformity Assessment Documents

FDA Warns of Infection Risk From Heater-Coolers

  • Post author:Sam
  • Post published:November 6, 2020
  • Post category:The GMP Letter

The FDA has raised concerns about the risk of infections associated with CardioQuip’s modular heater-cooler device. Source: The GMP Letter

Continue ReadingFDA Warns of Infection Risk From Heater-Coolers

Health Canada Updates Guidelines on COVID-19 Testing

  • Post author:Sam
  • Post published:November 6, 2020
  • Post category:The GMP Letter

Health Canada is fast-tracking the review of submissions related to rapid antigen detection tests (RADTs) and nucleic acid tests and has released new guidance on antigen testing. Source: The GMP…

Continue ReadingHealth Canada Updates Guidelines on COVID-19 Testing

UK Establishes New Medical Device Information System

  • Post author:Sam
  • Post published:November 6, 2020
  • Post category:The GMP Letter

The United Kingdom will launch a new Medical Device Information System (MDIS) in January that aims to improve device monitoring and performance and link them to patient outcomes. Source: The…

Continue ReadingUK Establishes New Medical Device Information System
  • Go to the previous page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.